Abstract. In several types of cancer cells, prostaglandins produced via the over-expression of epidermal growth factor receptor (EGFR) and cyclooxygenases regulate cell growth. We investigated the signaling mechanisms for the release of arachidonic acid (AA, a precursor for prostaglandins) in human cervical carcinoma HeLa cells. Treatment with EGF and 4β-phorbol 12-myristate 13-acetate (PMA) with A23187 released AA accompanied by the phosphorylation of extracellular signal-regulated kinases (ERK1/2). Pharmacological experiments showed that the responses (ERK phosphorylation and AA release) induced by EGF and PMA were mediated by a mitogen-activated protein kinase /ERK kinase (MEK) -ERK -α-type cytosolic phospholipase A 2 (cPLA 2 α) pathway and that EGFR couples with the pathway in a manner insensitive to sorafenib, an inhibitor of B-and C-Raf, enzymes upstream of MEK. Activation of protein kinase C by PMA couples with the pathway partly in a sorafenib-sensitive and probably C-Raf-mediated manner and partly in a family of Src tyrosine kinases (Src)-dependent and sorafenib-insensitive manner. Co-treatment with sorafenib and an inhibitor of Src family members additionally inhibited the PMA-induced release of AA. Cross-talk between EGFR and protein kinase C was not observed. In human lung carcinoma A549 cells, the release of AA by EGF was insensitive to sorafenib. Possible mechanisms for the sorafenib-insensitive activation of the MEK-ERK-cPLA 2 α pathway are discussed.
Introduction
The production of lipid mediators, the prostaglandins (PGs) and leukotrienes, has been implicated in the regulation of cell growth, inflammation, and tumor progression (1, 2) . There is much evidence that prostanoids, specifically PGs, are involved in the etiologies of cancer; and increased levels of PGs occur in various types of human cancer, including colon, pancreatic, and lung cancer. PGs are mainly formed by two processes, the release of arachidonic acid (AA) from phospholipids in cellular membranes by a family of phospholipase A 2 (PLA 2 ) enzymes and its conversion to PGs by cyclooxygenases (COXs). Carcinosarcoma of the uterus is an aggressive cancer containing both malignant epithelial and mesenchymal components. COX-2 is reported to be over-expressed in the epithelial component in 70% -90% of cases (3, 4) . In HeLa cells, a human cervical carcinoma cell line, a considerable amount of COX-2 exists endogenously, and PGs appeared to regulate cell fate in an autocrine/paracrine manner because inhibition of COX-2 induced cell death including apoptosis (5, 6) . In addition, activation of receptors by growth factors plays a key role in regulating tumor cell proliferation. The epidermal growth factor receptor (EGFR) is part of a family of closely related cell surface receptors, that is, EGFR (HER1 or erbB1), erbB2, erbB3, and erbB4. EGFR is a 170-kDa glycoprotein that possesses intrinsic tyrosine kinase activity, and a complex network of EGFR-associated protein interactions is one of the cellular systems controlling cell proliferation, differentiation, and so on. Thus, non-physiological activation of EGFR can lead to uncontrolled cell division and ultimately a growing tumor mass, and EGFR is often over-expressed in human tumors (7, 8) . In uterine carcinosarcoma, over-expression of EGFR in the epithelial and mesenchymal components was observed in 30% and 50% -70% of cases, respectively (3, 7) . The synchronous co-expression of EGFR and COX-2 in carcinomas of the uterine cervix may be a potential indicator of poor survival (8, 9) . These findings suggest changes of both EGFR and AA metabolism to be involved in the growth of cancer.
The liberation of AA from phospholipids occurs mainly through the activation of PLA 2 . In addition to the transcriptional regulation, the activity of PLA 2 is regulated by a number of extra-and intra-cellular stimuli such as cytokines, growth factors, oxidative stress, and hormones, and so on (10, 11) . The many PLA 2 s identified and characterized over the past two decades are now classified as secretory PLA 2 , cytosolic PLA 2 (cPLA 2 ), and Ca
2+
-independent PLA 2 (10, 11). Type α cPLA 2 (cPLA 2 α, type IV-A) plays a pivotal role in providing AA because of its selectivity for phospholipids containing AA at the sn-2 position. EGF has been reported to release AA and/or activate cPLA 2 α by phosphorylation within 30 min or several hours in many cell types including HeLa cells (12 -14) . In addition, receptor types of tyrosine kinases including EGFR are reported to regulate the time-dependent localization and activation of cPLA 2 α in cells (10 -12, 15) . cPLA 2 α is regulated by Ca 2+ and its phosphorylation mediated by mitogen-activated protein kinases (MAPKs), specifically extracellular signal-regulated kinase (ERK) and p38 kinase (10, 11, 16, 17) . Also, activated EGFR conveys signals mainly through the MAPK /ERK kinase (MEK) -ERK pathway (7, 8, 18) . MEK activity is regulated by enzymes upstream, a family of MEK kinases including Raf, which has three isoforms: A-Raf, B-Raf, and C-Raf (Raf-1). Mutations in B-Raf and C-Raf have been identified in various malignant tissues, although mutations in A-Raf have not (19 -21 ) is a dual-action inhibitor that targets Raf in tumor cells and tyrosine kinases of the vascular-endothelial growth factor receptor and platelet-derived growth factor receptor families (19, 22) . Sorafenib inhibited the kinase activity of both C-Raf and B-Raf (wild type and V600E mutant) with IC 50 values from 6 to 38 nM, although its effect on A-Raf has not been well established (19, 22) . It was reported that stimulation of HeLa cells with EGF activated A-Raf rather than C-Raf (23) and that the cellular responses including phosphorylation of ERK1/ 2 were sorafenibinsensitive in several types of cancer cells (22, 24) . The precise role of sorafenib in EGFR-mediated responses including the release of AA in cancer cells has not been elucidated. In the present study, we investigated the signaling mechanisms of EGF and 4β-phorbol 12-myristate 13-acetate [PMA, an activator of protein kinase C (PKC)] for the release of AA and the role of sorafenib-sensitive and -insensitive pathways in the release in HeLa cells. Also, the sorafenib-sensitivity of EGF-evoked responses was examined in human lung carcimoma A549 cells. Our findings showed that stimulation with EGFR and PMA-sensitive PKC was coupled with the common MEK-ERK-cPLA 2 α pathway, but EGFR preferentially activated sorafenib-insensitive upstream enzymes of MEK in a PKC-independent manner in HeLa cells. Activation of PKC was coupled with the MEK-ERK pathway both in the sorafenib-sensitive and probably C-Raf-mediated pathway and in the sorafenibinsensitive pathway that is regulated by a family of Src tyrosine kinases (Src). Possible sorafenib-insensitive mechanisms for activation of the MEK-ERK-cPLA 2 α pathway by EGF in HeLa cells are discussed.
Materials and Methods

Chemicals
The following chemicals and reagents were used: [5, 6, 8, 9, 11, 12, 14, H]AA (215 Ci /mmol, 7.96 TBq /mmol, Amersham, Buckinghamshire, UK); EGF (human, recombinant; Funakoshi, Tokyo); PMA, A23187, 2-(2-amino-3.methoxyphenyl)-4H-1-benzopyran-4 -one (PD098059), GF109203X, and 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB202190) (Sigma, St. Louis, MO, USA); pyrrophenone (a gift from Dr. K. Hanasaki, Shionogi Pharm. Ltd., Osaka); Go6976, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), 4-amino-7-phenylpyrazol [3,4-d] pyrimidine (PP3, a negative control for PP2), 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (tyrphostin AG1478), SU6656, and wortmannin (Calbiochem, San Diego, CA, USA); 1,4-diamino-2,3-dicyano-1,4-bis-(o-aminophenylmercapto) butadiene (U0126; Promega, Madison, WI, USA); sorafenib (American Chemicals Custom Corp., San Diego, CA, USA); and diclofenac (Cayman, Ann Arbor, MI, USA). Several reagents including PMA, A23187, and kinase inhibitors such as sorafenib and U0126 were dissolved in dimethyl sulfoxide. The reagents were diluted with the medium before the experiments, and the final concentration of dimethyl sulfoxide in the medium was less than 0.5%. The concentrations of reagents including inhibitors of kinases were the same as those in previous reports (16, 17, 25 -27) . The vehicles had no effect on the release of AA or phosphorylation of ERK with and without the stimuli at least for 30 min. In the experiments using A549 cells, cells were treated with 20 μM diclofenac, an inhibitor of COXs, overnight before the stimulation in order to reduce endogenous PG-mediated effects. In some experiments, the cells were pretreated with inhibitors for enzymes such as pyrrophenone and sorafenib for specific periods before the stimulation. The radioactivity in the supernatant (8,000 rpm, 2 min) and cell lysate (in 1% Triton X-100) was measured by liquid scintillation counting. The 3 H radioactivity released into the supernatant was expressed as a percentage of the total amount of radioactivity incorporated (approximately 100,000 dpm per well). In some cases, the amount of AA released is normalized as a percentage of the response induced by A23187/PMA.
Western blotting
Cell lysate (30 μg of protein per lane) was fractionated by SDS-PAGE and transferred to PVDF membranes. The blocked membranes were then incubated with the following antibodies (1:300 -1:500): anti-ERK1 and anti-ERK2 antibodies (C-16 and C-14; Santa Cruz Biotech, Santa Cruz, CA, USA) and anti-phospho- 
Data presentation
Each reported value is the mean ± S.E.M. for the indicated number of experiments performed in triplicate. In the case of multiple comparisons, the significance of differences was determined by one-way analysis of variance with Dunnett's or Tukey's test. For pairwise comparisons, Student's two-tailed t-test was used. Pvalues <0.05 were considered to be significant. In some cases, data are shown as the mean ± S.D. of three determinations in a representative experiment.
Results
EGF released AA via activation of the MEK-ERKcPLA 2 α pathway in a PKC-independent manner
In the presence of 100 nM A23187, treatment of HeLa cells with 10 nM PMA or 20 ng/mL of EGF for 30 min markedly released AA (Fig. 1A) . Although A23187 at concentrations greater than 200 nM by itself released AA, the response induced by 100 nM A23187 was limited. Treatment with PMA or EGF had no effect without A23187. In subsequent experiments, we investigated the signaling mechanisms of PMA and EGF for the release of AA in the presence of 100 nM A23187. Treatment with EGF did not have an additional stimulatory effect on the release of AA induced by PMA; the value obtained with PMA /EGF was 14.5 ± 1.3 (% of total incorporated, n = 4). Treatment with 2 μM pyrrophenone, a selective inhibitor of cPLA 2 α, slightly inhibited the basal release of AA without stimuli, and markedly inhibited the release of AA induced by PMA and by EGF (Fig. 1B) . Since the absolute values of the release with and without the stimuli varied with each experiment, the release was calculated as a percentage of the response to PMA for quantitative analyses ( Table 1) . The basal release without the stimuli and the response to EGF were 9.8 ± 2.1% and 54.8 ± 3.2% of the PMAelicited response, respectively. The release of AA induced by PMA and EGF in the presence of pyrrophenone was less than 10% of the PMA-evoked response, the same as the basal release ( Fig. 1 and Table 1 ). As mentioned in the Introduction, the MEK-ERK pathway regulates the activation of cPLA 2 α in many cell types (10, 26, 27) . Treatment with both PMA and EGF caused phosphorylation of ERK1/2 within 10 min, and the response continued for at least 30 min ( (Table 1) . Taking the basal and/or pyrrophenone-insensitive release of AA into account, the net increases induced by PMA and EGF were over 80% and almost completely inhibited by U0126, respectively. Similarly, treatment with U0126 almost completely inhibited the phosphorylation of ERK1/ 2 induced by PMA and by EGF (Fig. 2C) . Treatment with 10 μM PD098059, an inhibitor of MEK1, effectively inhibited both the PMA-and EGFinduced release of AA over 60% (data not shown). These results suggest that PMA and EGF both activate cPLA 2 α via a common MEK-ERK pathway.
Treatment with GF109203X, a general inhibitor of PKC, inhibited the release of AA induced by PMA in a concentration-dependent manner (Fig. 3A) , and the net increase by PMA was almost completely inhibited by treatment with 1 μM GF109203X (Fig. 3B) . By contrast, GF109203X at concentrations lower than 3 μM did not inhibit the EGF-induced release of AA, and at 10 μM, it inhibited both the response induced by PMA and that induced by EGF. GF109203X at 3 μM inhibited the phosphorylation of ERK1/2 induced by PMA, but not by EGF (Fig. 2D) . The PMA-induced release of AA was inhibited approximately 70% by the treatment with 1 μM Go6976, a selective inhibitor of PKCα/β, and the response was almost completely abolished in the PKCdepleted cells (conventional and novel types of PKCdepleted cells), which were cultured with 10 nM PMA for 16 h before the assay for the release of AA (Fig. 3C ). Neither treatment with Go6976 nor the depletion of PKC changed the EGF-induced release of AA (Fig. 3C) or the phosphorylation of ERK1/ 2 (data not shown). These results suggest that EGF releases AA via the MEK-ERK-cPLA 2 α pathway, but the response to EGF was independent of PMA-sensitive PKCs. Labeled HeLa cells were treated with vehicle, 10 nM PMA, and 20 ng / mL of EGF with 100 nM A23187 for 30 min. In some experiments, cells were cultured with the indicated inhibitors for 30 min before stimulation. Each data value is the mean ± S.E.M. for the indicated numbers of independent experiments performed in triplicate. a P<0.05, significantly different from the value without the inhibitors. The value without the stimuli was 1.5% -2.5% (% of total incorporated AA), corresponding to 9.8 ± 2.1% (8% -14% of the response with A23187 /PMA, n = 10).
Role of EGFR and Src in PMA-and EGF-induced responses
Treatment of HeLa cells with 1 μM of AG1478, a potent and specific inhibitor of EGFR tyrosine kinase activity, markedly (by over 70%) inhibited the EGFinduced release of AA (Table 1 ) and the phosphorylation of ERK1/2 (Fig. 2E) , but did not inhibit the PMAinduced responses. Treatment with SU6656, an inhibitor of Src family members, inhibited the PMA-induced, but not EGF-induced, release of AA in a concentrationdependent manner (Fig. 4A) . The inhibitory effect of 10 μM SU6656 on the response to PMA was marked and significant, and part of the PMA-evoked response was resistant to treatment with SU6656 (Fig. 4B) . Treatment with 20 μM SU6656 by itself released AA without the stimuli and did not have any additional inhibitory effect on the response to PMA compared to that with 10 μM SU6656 (data not shown). Treatment with 10 μM PP2, another inhibitor of Src family members, significantly inhibited the PMA-induced, but not EGF-induced, release of AA (Fig. 4B) . Treatment with PP3, a negative control for PP2, did not inhibit the response to PMA (data not shown). Surprisingly, treatment with SU6656 changed neither the PMA-nor EGF-induced phosphorylation of ERK1/2 at 10 min after stimulation (Fig. 2F) or at 30 min after PMA treatment (data not shown). Similar results were obtained in the absence of A23187, and the effect of PP2 on PMA-induced phosphorylation of ERK1/2 was marginal (data not shown). Neither the inhibitor for p38 kinase (SB202190 at 10 μM) nor that for phosphatidylinositol 3-kinase (wortmannin at 100 nM) affected the release of AA induced by the stimuli ( Table 1 ). The phosphorylation of ERK1/2 by PMA and by EGF was not modified by wortmannin (Fig. 2G ) or SB202190 (data not shown) either.
Inhibition of PMA, but not EGF, -induced responses by sorafenib in HeLa cells
Treatment of HeLa cells with sorafenib (BAY 43-9006, Nexavar ® ), an inhibitor of B-Raf and C-Raf (22) , inhibited the release of AA induced by PMA, but not by EGF, in a concentration-dependent manner (Fig. 5A) . The inhibitory effect of sorafenib was significant at 1 μM, and treatment with 5 μM sorafenib half inhibited the PMA-evoked response (Fig. 5B) . Treatment with 10 μM sorafenib did not have an additional inhibitory effect and by itself only slightly released AA. The value obtained with 10 μM sorafenib was 3% -5% of the total incorporated AA and thus 19.5 ± 2.9% of the A23187 /PMA response (n = 8). Interestingly, the values for the PMA-induced release of AA in the cells co-treated with 5 μM sorafenib and 10 μM SU6656 were 14.6% and 16.6% (% of the A23187/PMA response) in two independent experiments. Treatment with 5 μM sorafenib markedly inhibited the phosphorylation of ERK1/2 induced by PMA, but not by EGF (Fig. 2H) . The sensitivity of the PMA-induced phosphorylation of ERK1/2 to sorafenib varied slightly, being 30% -40% of the control response without sorafenib in three independent experiments, and about 60% -70% in the other two experiments. EGF-induced ERK phosphorylation with sorafenib was 85% -95% (n = 3) of that in the control without sorafenib.
Sorafenib-insensitive release of AA induced by EGF in human lung carcinoma A549 cells
Numerous studies described abundant expression of EGFR in human non-small-cell lung carcinoma A549 cells and that the stimulation of A549 cells with EGF released AA via cPLA 2 α's activation accompanied by the phosphorylation of ERK (13, 28) . Under our conditions, treatment with 1 μM A23187 by itself released AA in A549 cells, and co-treatment with 100 nM PMA or 200 μg/mL of EGF in the presence of A23187 markedly released AA ( Table 2 ). The release of AA induced by PMA and by EGF in the presence of A23187 was inhibited over 80% by treatment with 5 μM pyrrophenone or 10 μM U0126 (data not shown). Treatment with 5 μM sorafenib significantly inhibited the A23187 /PMA-induced release and slightly inhibited the response to A23187. Like in HeLa cells, treatment with sorafenib did not inhibit the A23187/EGF-induced release in A549 cells. Treatment of A549 cells with EGF and PMA caused phosphorylation of ERK1/2 within 10 min (Fig. 2I) , and the responses peaked at 5 -15 min and continued for at least 20 min (data not shown). Surprisingly, treatment with sorafenib from 1 μM markedly inhibited the phosphorylation of ERK1/ 2 induced not only by PMA but also that by EGF in A549 cells (Fig. 2I) .
Discussion
In the present study, we propose a model schema (Fig. 6) for the PMA-and EGF-induced release of AA in HeLa cells. PMA stimulates PKCs, resulting in activation of the MEK-ERK-cPLA 2 α pathway in two ways: one being mediated by a sorafenib-sensitive protein, probably C-Raf, and the other being sorafenib-insensitive. Since the sorafenib-insensitive release of AA was inhibited by the inhibitors of Src family members, the two appeared to act independently in the PMA-stimulated cells, and cross-talk between Src and PKC exists in the cells. Stimulation of EGFR activates sorafenibinsensitive molecules having MEK kinase activity, resulting in activation of the MEK-ERK-cPLA 2 α pathway in a PKC-and Src-independent manner. EGF-induced activation of the MEK-ERK-cPLA 2 α pathway in a PKC-and Src-independent manner in HeLa cells
Treatment of HeLa cells with EGF resulted in the phosphorylation of ERK1/2 within 10 min (Fig. 2) and release of AA for 30 min in the presence of a Ca 2+ ionophore (Fig. 1) , as previously shown (14) . Since the EGF-induced release of AA was almost completely inhibited by pyrrophenone and by U0126, the release was mediated by the MEK-ERK-cPLA 2 α pathway in a P<0.05, significantly different from the value without Src inhibitors. In the absence of A23187 /PMA, values were 12.9 ± 1.6 (% of the A23187 / PMA response, n = 8) in the control cells, 13.2 ± 1.3% (n = 5) in the 10 μM SU6656-treated cells, and 13.7 ± 2.9% (n = 5) in the 10 μM PP2-treated cells. HeLa cells, as in many other cell types (10 -15) . A role for the phosphatidylinositol 3-kinase and the p38 MAP kinase pathways in the PMA-and EGF-induced activation of cPLA 2 α was ruled out. The activation of PKC has been shown to be linked to the trans-activation of EGFR in several cell types (29, 30) , and the activation of EGFR is capable of signaling to PKC via the production of diacylglycerol mediated by the activation of γ-type phospholipase C (31). The PMA-induced phosphorylation of ERK1/2 (Fig. 2D ) and resulting release of AA (Fig. 3) were almost completely inhibited by inhibition of the conventional and/or novel types of PKC (PKC inhibitors and PMA-sensitive PKC depletion), but the responses to EGF were not changed by the inhibition of PKC. In addition, treatment with AG1478, an inhibitor of EGFR tyrosine kinase, markedly attenuated the responses to EGF but not PMA (Table 1 and Fig. 2E ). Thus, possible bi-directional cross-talk between EGFR and PKC appears unlikely in HeLa cells.
Src has been shown to participate in signaling from EGFR in many cell types including HeLa cells, and Src phosphorylated Tyr residues of EGFR and regulated the receptor's functions (32, 33) . However, our results suggest that Src family members were not involved in the signaling pathways activated by EGF and coupled with the MEK-ERK-cPLA 2 α pathway in HeLa cells. Previously, we reported that hydrogen peroxide (26) and orthovanadate (an inhibitor of protein tyrosine phosphatases, Ref. 27) activated cPLA 2 α in a Src-and PKCdependent manner in L929 mouse fibrosarcoma cells. In the present study, the Src-dependent pathway was involved in the PKC-mediated pathway for cPLA 2 α's activation in HeLa cells, like in L929 cells. Our data also suggest that the EGF-induced activation of the MEK-ERK-cPLA 2 α pathway was dependent on neither PKC nor Src.
Sorafenib-insensitive proteins upstream of the MEK-ERK pathway in HeLa cells
Many proteins are involved in the signaling between upstream of the MEK-ERK pathway and downstream of PKC and/or EGFR (8, 20, 21, 34) , including the Raffamily (A-Raf, B-Raf, and C-Raf). Large amounts of A-Raf and C-Raf are endogenously expressed, and BRaf is expressed at a very low (undetectable) level in HeLa cells (23, 35) . It has been established that PMAactivated PKC isoforms such as the α-type and β-type can directly phosphorylate and activate C-Raf in vitro and in cells including HeLa cells (20, 36) . Stimulation with PMA (and EGF), not A23187, increased the MEKactivating activity of A-Raf and C-Raf in HeLa cells (23) . Our results obtained with PKC inhibitors and PKC-depletion suggest that a large part of the responses to PMA (activation of the ERK-cPLA 2 α pathway) was mediated by conventional and/or novel PKCs in HeLa cells. Although PMA is known to bind and activate Ras guanyl-releasing protein (RasGRP) in a PKCindependent manner, resulting in the activation of C-Raf by Ras-GTP (37), our data exclude the involvement of the PKC-independent activation of C-Raf in the PMAevoked responses tested. It is reported that sorafenib inhibits the activities of B-and C-Raf proteins including the autophosphorylation of Ser 338 and Ser 445 (22, 38) . In preliminary experiments, treatment with sorafenib decreased the intensity of a band that cross-reacted with anti-phospho-C-Raf (Ser
338
) antibody (data not shown). In HeLa cells, the phosphorylation of ERK and the activation of cPLA 2 α induced by PKC's activation appeared to be mediated partially by sorafenib-sensitive factors, probably C-Raf.
Interestingly, we found both the phosphorylation of ERK and activation of cPLA 2 α induced by EGF to be less sensitive to sorafenib and the PMA-induced release of AA to be partly sorafenib-insensitive in HeLa cells (Figs. 2 and 5) . There are several possible sorafenibinsensitive mechanisms for MEK-ERK's activation. The regulation of Raf proteins including C-Raf is complex and involves various mechanisms (20, 21, 39) ; for instance, the activity of Raf is regulated by various factors including scaffolding proteins and heat shock proteins, in addition to Ras proteins. Furthermore, there are many kinases that can activate the MEK-ERK pathway in addition to Raf proteins in cells (39, 40) , and the MEK-ERK pathway in HeLa cells is regulated by endogenous Cot/tpl-2 (MAPKKK; Refs. 41, 42) . Thus, activation of EGFR may stimulate complexes of Raf proteins and/or other MEK kinases that are sorafenibinsensitive in HeLa cells. The sensitivity to sorafenib of A-Raf, Raf complexes, and other MEK kinases should be determined in the future. Another possibility is that the movement of EGFR including the formation of endocytotic complexes triggers the formation of sorafenibinsensitive complexes that have MEK kinase activity and effectively couple with the MEK-ERK-cPLA 2 α pathway. Endocytosis of EGFR and the ERK signaling after EGF stimulation are closely related in HeLa cells (43, 44) . In mitotic HeLa cells, treatment with PMA resulted in a marked but delayed activation of ERK, although the response to EGF was completely inhibited compared with that in asynchronous cells (36) . Recently, it was reported that EGFR-and PKC-mediated signaling to ERK is regulated by different mechanisms in HeLa cells: different coupling with phosphatases and different spatiotemporal-dependency (45) . cPLA 2 α existed in the cytosol before stimulation, and Ca
2+
-activated cPLA 2 α mainly located in the perinuclear regions including the Golgi complex (10, 11, 25) . The role of the ERK pathway-related proteins including MEK kinase in cPLA 2 α's activation in specified areas such as the Golgi complex should be examined.
Several studies have provided evidence for Ras isoform-specific signaling that is regulated by different intracellular compartments and coupling proteins (34, 46, 47) . In HeLa cells, treatment with a Ras inhibitor augmented autophagy independent of the classical Ras/ C-Raf pathway (48) . Although the EGFR-Sos-Ras pathway exists in various cells including HeLa cells (7, 18, 46) , preferential types of Ras for EGFR-Ras interaction have not been well examined. Thus, EGFR's activation and the PKC-mediated pathway may have stimulated specific Ras proteins that preferentially coupled to sorafenib-insensitive molecules having MEK kinase activities in HeLa cells. Alternatively, proteins without MEK kinase activity that are activated in the EGFR-mediated pathway may directly couple with the MEK-ERK pathway in HeLa cells.
Unsolved problems in this study
Several problems with the present study remain to be solved. First, sorafenib effectively inhibited the EGFand PMA-induced phosphorylation of ERK in A549 cells (Fig. 2I ). However, the basal level of ERK1/ 2 phosphorylation, which was marked because of the KRas mutation, was insensitive to sorafenib in A549 cells (22, 24) . The mechanism(s) regulating the sorafenibsensitive and -insensitive ERK pathways remain to be elucidated. Second, treatment with inhibitors of Src family members such as SU6656 inhibited by at least half the PMA-induced release of AA (Fig. 4) , but not PMA-induced phosphorylation of ERK, in HeLa cells (Fig. 2F) . The direct phosphorylation of tyrosine residue(s) and resulting activation of A-and C-Raf induced by Src is proposed (20, 49) . Although our results can exclude any direct activation of the Raf-MEK-ERK pathway by Src, it is unclear why SU6656 did not inhibit the PMA-induced phosphorylation of ERK in HeLa cells. Src kinases, classified as cytosolic enzymes, show dynamic intracellular movements in cells after stimulation, and they are found in endomembranes such as the Golgi complex and endosomes (50) . Cellular compartments of MEK kinases and Src may mask the possible effects of inhibitors of Src family members on the PMA-induced phosphorylation of ERK in HeLa cells. In addition, it should be determined whether the proposed sorafenib-insensitive proteins and/or pathways that are regulated by Src down-stream of PKC are the same as those mediated by EGFR stimulation.
Another problem is that treatment with sorafenib almost completely inhibited the PMA-induced phosphorylation of ERK, but only half inhibited the release of AA in HeLa cells. This may mean that other phosphorylation signals, in addition to the MEK-ERK pathway, are coupled with the phosphorylation of cPLA 2 α in cells treated with stimuli such as PMA. There are many sites of phosphorylation by kinases in cPLA 2 α, the main three being Ser 505 phosphorylated by ERK and p38 kinase, Ser 727 phosphorylated by p38-activated protein kinases such as MNK1 and closely related kinases, and Ser 515 phosphorylated by calmodulin kinase II (10, 11, 17) , although we reported that the effect of calmodulin kinase II on the enzyme was independent of Ser 515 (17). Xu et al. (51) proposed that both PKC and ERK can independently phosphorylate cPLA 2 α, and part of the release of AA induced by PMA without Ca 2+ was not mediated by the MEK-ERK pathway in primary murine astrocytes. In their experiments, inhibition of p38 kinase had little effect on cPLA 2 α's phosphorylation by PMA, thus kinases other than p38 kinase and related kinases such as MNK1 may regulate the phosphorylation. Possible kinases in the sorafenib-insensitive pathways that can phosphorylate and regulate cPLA 2 α activity in cooperation with the phosphorylation of Ser 505 induced by ERK need to be identified. In addition, the Ca
2+
regulated signals may differently regulate cPLA 2 α activity induced by EGF and by PMA. Recently, we reported that treatment with Ca 2+ ionophore stimulated formation of ceramide-1-phosphate via ceramide kinase, and ceramide-1-phosphate is a stimulatory factor on cPLA 2 α (25, 52). Sensitivity of cPLA 2 α to ceramide-1-phosphate may be dependent on phosphorylation levels and/or sites of the enzyme.
